User: Guest  Login
Title:

Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.

Document type:
Article; Clinical Trial, Phase III; Randomized Controlled Trial; Journal Article
Author(s):
Weller, J; Schäfer, N; Schaub, C; Tzaridis, T; Zeyen, T; Schneider, M; Potthoff, A L; Giordano, F A; Steinbach, J P; Zeiner, P S; Kowalski, T; Sabel, M; Hau, P; Krex, D; Grauer, O; Goldbrunner, R; Schnell, O; Tabatabai, G; Ringel, F; Schmidt-Graf, F; Brehmer, S; Tonn, J C; Bullinger, L; Vajkoczy, P; Glas, M; Vatter, H; Herrlinger, U; Seidel, C
Abstract:
PURPOSE: In the randomized phase III trial CeTeG/NOA-09, temozolomide (TMZ)/lomustine (CCNU) combination therapy was superior to TMZ in newly diagnosed MGMT methylated glioblastoma, albeit reporting more frequent hematotoxicity. Here, we analyze high grade hematotoxicity and its prognostic relevance in the trial population. METHODS: Descriptive and comparative analysis of hematotoxicity adverse events ≥ grade 3 (HAE) according to the Common Terminology of Clinical Adverse Events, version 4.0 was...     »
Journal title abbreviation:
J Neurooncol
Year:
2023
Journal volume:
161
Journal issue:
1
Pages contribution:
147-153
Fulltext / DOI:
doi:10.1007/s11060-022-04203-4
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/36609807
Print-ISSN:
0167-594X
TUM Institution:
1411; 1533; Klinik und Poliklinik für Neurologie (Prof. Hemmer)
 BibTeX